Result of AGM
RNS & Investor News
28 August 2019
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it received notification today that Frédéric Narbel, a Director of the Company, acquired 17,000 ordinary shares in the Company today, representing 0.02% of the Company's issued share capital, at a price of 50 pence per share.
Following the transaction, Mr Narbel is interested in 29,000 ordinary shares in the Company, representing 0.03% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP (NOMAD)||Tel: 020 7213 0880|
|Liam Murray / Jo Turner / Ludovico Lazzaretti|
|finnCap (Broker)||Tel: 020 7220 0500|
|Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
|goetzpartners securities Limited||Tel: 0203 859 7725|
|Walbrook PR Ltd
|Mob: 07876 741 001|
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
|Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014|
|1||Details of the person discharging managerial responsibilities/person closely associated|
|a.||Name||Frédéric André Narbel|
|2||Reason for notification|
|a.||Position/Status||Director of the Company|
|b.||Initial notification/ Amendment||Initial Notification|
|3||Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor|
|a.||Name||OptiBiotix Health Plc|
|4||Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted|
|a.||Description of the financial instrument, type of instrument
|17,000 ordinary shares of 2p each
|b.||Nature of the transaction||Purchase of 17,000 ordinary shares in the Company|
|c.||Price(s) and volume(s)|
|Price(s) per share||Volume(s)|
|e.||Date of the transaction||28 August 2019|
|f.||Place of the transaction||London Stock Exchange, AIM|
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020